Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.

4894 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cuorips Inc. is a regenerative medicine company engaged in the research, development, manufacturing, and commercialization of cell-based therapeutic products. The company specializes in advanced technologies involving induced pluripotent stem (iPS) cells. Its flagship development is the world's first iPS cell-derived cardiomyocyte sheet, a novel treatment targeting severe heart failure. In addition to its own product pipeline, Cuorips is involved in optimizing manufacturing and quality processes and offers contract development services to contribute to the broader advancement of medicine.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Cuorips Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-25 08:39
Regulatory News Service
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
Regulatory News Service
確認書
Japanese 8.1 KB
2025-06-20 08:38
Regulatory News Service
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
Annual Report
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
Regulatory News Service
確認書
Japanese 8.1 KB
2024-11-14 02:24
Interim Report
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
Regulatory News Service
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
Regulatory News Service
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
Regulatory News Service
確認書
Japanese 8.1 KB
2024-06-27 09:36
Annual Report
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
Regulatory News Service
確認書
Japanese 8.1 KB
2024-02-13 07:36
Quarterly Report
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
Regulatory News Service
確認書
Japanese 8.2 KB
2023-11-10 08:23
Quarterly Report
四半期報告書-第8期第2四半期(2023/07/01-2023/09/30)
Japanese 153.3 KB
2023-08-10 09:08
Regulatory News Service
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom HEMO
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland HRTIS
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan 4530
H. Lundbeck A Logo
Develops and commercializes innovative therapeutics for brain diseases globally.
Denmark HLUN
Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation ISKJ
Hong Kong N/A
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland IDIA

Talk to a Data Expert

Have a question? We'll get back to you promptly.